APM Medichem

Based in India, APM Medichem is a WHO-GMP certified manufacturer specializing in pharmaceuticals and nutritional products, offering a variety of formulations to meet diverse healthcare needs. Founded in 2024 in Haryana, India, APM Medichem focuses on manufacturing high-quality pharmaceuticals and nutraceuticals. The company successfully raised INR 220,000 in pre-seed funding from Antler in January 2025, marking its first deal in the industry. APM Medichem specializes in the manufacture of pharmaceuticals and nutritional products, primarily focusing on WHO-GMP certified formulations.

The company offers a broad range of products, including tablets, ointments, oral liquids, dry syrups, and capsules, designed to meet the needs of both pharmaceutical and nutraceutical brands. These products cater to various therapeutic areas and are essential for end users seeking reliable medication and health supplements. APM Medichem serves a diverse client base, including leading pharmaceutical and nutraceutical companies, and operates in international markets, particularly in regions classified as Rest of the World (ROW) and semi-regulated markets. The company’s solutions are built on a foundation of regulatory compliance, enabling faster speed-to-market and addressing the growing demand for high-quality, cost-effective healthcare products.

APM Medichem generates revenue through B2B transactions, partnering with pharmaceutical and nutraceutical brands to deliver customized manufacturing solutions. The transaction structure primarily involves direct partnerships, where clients benefit from APM Medichem's capabilities in API and nutraceutical ingredient sourcing, as well as its integrated manufacturing processes. Pricing plans for individual products are aligned with market standards, reflecting the company's commitment to quality and compliance. The firm’s flagship products include a variety of formulations that not only address specific health concerns but also enhance the brands’ overall offerings.

Transactions typically encompass bulk orders, enabling clients to maintain competitive pricing while ensuring a steady supply of essential health products. In January 2025, APM Medichem raised INR 220,000 in pre-seed funding from Antler to support its growth initiatives. The company plans to introduce new formulations targeting specific health areas and to expand its market reach into semi-regulated regions across Asia and Africa by the end of 2025. The recent funding will enable APM Medichem to enhance its manufacturing capabilities and accelerate product development efforts.